Heron Therapeutics
HRTX
104 hedge funds and large institutions have $1.02B invested in Heron Therapeutics in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 12 closing their positions.
667% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $1.58M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
6% more capital invested
Capital invested by funds: $964M → $1.02B (+$59.8M)
0% more funds holding
Funds holding: 104 → 104 (0)
12.53% less ownership
Funds ownership: 129.64% → 117.12% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$5.18M |
| 2 |
Millennium Management
New York
|
+$3.15M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.14M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.88M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$46.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.6M |
| 3 |
BC
Broadfin Capital
New York
|
-$15.1M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$11.8M |
| 5 |
Citigroup
New York
|
-$5.21M |
HRTX Hedge Fund Activity: Q3 2017 in Review
104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2017, worth a combined $1.02B — up 6.2% from $964M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new HRTX positions and 12 closed out — a net gain of 2 holders — while 35 added to existing stakes and 31 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.18M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $46.3M sold.
- 104 institutional investors held Heron Therapeutics (HRTX) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $1.02B of Heron Therapeutics stock for Q3 2017, up 6.2% quarter-over-quarter.
- 14 funds opened new Heron Therapeutics positions in Q3 2017 and 12 closed out, a net change of +2 holders.
- The largest Heron Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $5.18M added.
- The largest Heron Therapeutics seller in Q3 2017 was PFM Health Sciences, an estimated $46.3M sold.
Based on aggregated 13F filings for Q3 2017.